Glenmark Pharmaceuticals Inc. USA (Glenmark), a subsidiary of Glenmark Pharmaceuticals Ltd., today announced the upcoming launch of Ropivacaine Hydrochloride Injection USP, available in 40 mg/20 mL (2 mg/mL), 150 mg/30 mL (5 mg/mL), and 200 mg/20 mL (10 mg/mL) single-dose vials. Distribution is scheduled to begin in November 2025.

Glenmark’s Ropivacaine Hydrochloride Injection USP is bioequivalent and therapeutically equivalent to the reference listed drug Naropin Injection (40 mg/20 mL, 150 mg/30 mL, and 200 mg/20 mL), of Fresenius Kabi USA.

According to IQVIA sales data for the 12-month period ending August 2025, the Naropin Injection market achieved annual sales of approximately $20.9 million.

Commenting on the launch, Marc Kikuchi, President & Business Head, North America, Glenmark Pharmaceuticals Inc., USA, said: “We are pleased to introduce Ropivacaine Hydrochloride Injection USP to the U.S. market. This launch marks another important step in strengthening our growing injectable portfolio and underscores our commitment to providing patients and healthcare providers with high-quality, affordable alternatives.”

This launch further enhances Glenmark’s position in the U.S. generic injectables segment and reflects the company’s ongoing focus on expanding access to essential hospital and critical care medications.